RxDoctor Payments Data

Elaine Larkins, APRN

Family · Quincy, FLNPI 1780688341

Payments from drug & device makers

$861in general payments, 2019–2025

Across 49 payments — averaging $17.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$291
  • Merck$215
  • Dexcom, Inc.$56
  • Sanofi Pasteur Inc.$45
  • AbbVie$45
  • Kowa Pharmaceuticals America, Inc.$42
  • plus $167 from 7 others

What the payments were for

  • Food & beverage$861100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$861 in reported general payments places this provider in the 65th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$932
Medicare patients
37
Services billed
196

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol154$153,780
JanuviaSitagliptin Phosphate99$128,691
JardianceEmpagliflozin58$80,436
EliquisApixaban55$61,893
EntrestoSacubitril/Valsartan24$31,356
OzempicSemaglutide18$27,955
Breztri AerosphereBudesonide/Glycopyr/Formoterol30$22,228
LinzessLinaclotide18$19,707
RybelsusSemaglutide11$18,606
Tresiba Flextouch U-100Insulin Degludec34$16,871
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$10,147
SymbicortBudesonide/Formoterol Fumarate35$9,864
Advair HfaFluticasone Propion/Salmeterol14$9,123
NamzaricMemantine Hcl/Donepezil Hcl12$8,083
TradjentaLinagliptin14$7,936

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$215$128,69199 claims
Boehringer IngelheimJardiance, Tradjenta$34$88,37272 claims
PfizerEliquis$37$61,89355 claims
Novo NordiskOzempic, Rybelsus$291$46,56129 claims
NovartisEntresto$26$31,35624 claims
AbbVieLinzess, Namzaric$45$27,79030 claims
GSKTrelegy Ellipta$18$10,14716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 14,618 family providers in Florida.

Other family in Quincy

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →